Vaccine plus immunotherapy for glioblastoma after standard treatment
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new vaccine (UCPVax) with or without pembrolizumab (an immunotherapy) given after standard radiation and chemotherapy for people with a specific type of glioblastoma (MGMT unmethylated). The goal is to see if adding these treatments can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of glioblastoma that has a normal IDH gene and an unmethylated MGMT gene.
- You have completed radiation and chemotherapy (temozolomide) and are ready to start maintenance chemo.
- You are able to do most daily activities on your own (Karnofsky score of 70% or higher).
- If you take steroids, your dose has been stable for at least 2 weeks and is not more than 10 mg of prednisone per day.
- You are not pregnant, and you and your partner agree to use effective birth control during treatment and for several months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests an experimental vaccine for glioblastoma, given after the usual radiation and chemotherapy (temozolomide). The goal is to see if the vaccine helps the immune system fight remaining cancer cells.
This trial tests a new immunotherapy that targets the CMV virus inside your glioblastoma tumor. It is for people who have already completed standard radiation and chemotherapy.
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
This trial tests whether adding a personalized vaccine made from your own immune cells and tumor can help standard chemotherapy and radiation work better against glioblastoma. It is for patients who have already had surgery and are starting or have just finished their first round of chemoradiation.
This study tests a combination treatment for glioblastoma, a type of brain cancer. It includes a personalized vaccine made from your tumor, along with chemotherapy and an immunotherapy drug (anti-PD-1). The goal is to see if this combination helps people with this cancer.
Hear when a new Primary Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.